Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study

Alzheimer's and Dementia

Volumn 11, Issue 8, 2015, Pages 964-974

  Sabri, Osama ^a   Sabbagh, Marwan N ^b   Seibyl, John ^c   Barthel, Henryk ^a   Akatsu, Hiroyasu ^d,e   Ouchi, Yasuomi ^f   Senda, Kohei ^g   Murayama, Shigeo ^h,i   Ishii, Kenji ⁱ   Takao, Masaki ^i,j   Beach, Thomas G ^b   Rowe, Christopher C ^k   Leverenz, James B ^l,r   Ghetti, Bernardino ^m   Ironside, James W ⁿ   Catafau, Ana M ^o   Stephens, Andrew W ^o   Mueller, Andre ^o   Koglin, Norman ^o   Hoffmann, Anja ^p   Roth, Katrin ^p   Reininger, Cornelia ^p   Schulz Schaeffer, Walter J ^q   more..

^a UNIVERSITY OF LEIPZIG   (Germany)

^b SUN HEALTH RESEARCH INSTITUTE   (United States)

^c Molecular NeuroImaging LLC   (United States)

^d NAGOYA CITY UNIVERSITY   (Japan)

^e NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^f HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g Koseikai Hospital Diagnostic Imaging Center   (Japan)

^h Tokyo Metropolitan Institute of Gerontology   (Japan)

ⁱ TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^j Mihara Memorial Hospital   (Japan)

^k UNIVERSITY OF MELBOURNE   (Australia)

^l UNIVERSITY OF WASHINGTON   (United States)

^m INDIANA UNIVERSITY   (United States)

ⁿ UNIVERSITY OF EDINBURGH   (United Kingdom)

^o Piramal Enterprises Limited   (India)

^p BAYER PHARMA AG   (Germany)

^q UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^r LERNER RESEARCH INSTITUTE   (United States)

more..

Author keywords

Amyloid; Florbetaben; Histopathology; PET

Indexed keywords

AMYLOID BETA PROTEIN; FLORBETABEN; 4-(N-METHYLAMINO)-4'-(2-(2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)STILBENE; ANILINE DERIVATIVE; STILBENE DERIVATIVE;

ADULT; AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; BRAIN ANALYSIS; CONTROLLED STUDY; DEMENTIA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; ANALYSIS OF VARIANCE; BRAIN; CLINICAL TRIAL; COHORT ANALYSIS; DIAGNOSIS; IMAGE PROCESSING; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PSYCHOLOGICAL RATING SCALE; RADIOGRAPHY; RECEIVER OPERATING CHARACTERISTIC; SCINTISCANNING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; ANILINE COMPOUNDS; BRAIN; COHORT STUDIES; DIAGNOSIS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; ROC CURVE; STILBENES;

EID: 84939264152     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2015.02.004     Document Type: Article

References (31)

1. R. Vandenberghe, K. Adamczuk, P. Dupont, K.V. Laere, and G. Chetelat Amyloid PET in clinical practice: its place in the multidimensional space of Alzheimer's disease Neuroimage Clin 2 2013 497 511
2. P.L. McGeer, and E.G. McGeer The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy Acta Neuropathol 126 2013 479 497
3. B. Dubois, H.H. Feldman, C. Jacova, J.L. Cummings, S.T. Dekosky, P. Barberger-Gateau, and et al. Revising the definition of Alzheimer's disease: a new lexicon Lancet Neurol 9 2010 1118 1127
4. B. Dubois, H.H. Feldman, C. Jacova, H. Hampel, J.L. Molinuevo, K. Blennow, and et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria Lancet Neurol 13 2014 614 629
5. C.R. Jack Jr. Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play Radiology 263 2012 344 361
6. N. Nelissen, L.K. Van, L. Thurfjell, R. Owenius, M. Vandenbulcke, M. Koole, and et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease J Nucl Med 50 2009 1251 1259
7. Z. Cselényi, M.E. Jönhagen, A. Forsberg, C. Halldin, P. Julin, M. Schou, and et al. Clinical validation of 18F-AZD4694, an amyloid-beta-specific PET radioligand J Nucl Med 53 2012 415 424
8. D.F. Wong, A.R. Moghekar, D. Rigamonti, J.R. Brašić, O. Rousset, W. Willis, and et al. An in vivo evaluation of cerebral cortical amyloid with [18F]flutemetamol using positron emission tomography compared with parietal biopsy samples in living normal pressure hydrocephalus patients Mol Imaging Biol 15 2013 230 237
9. G.W. Small, V. Kepe, L.M. Ercoli, P. Siddarth, S.Y. Bookheimer, K.J. Miller, and et al. PET of brain amyloid and tau in mild cognitive impairment N Engl J Med 355 2006 2652 2663
10. H. Barthel, J. Luthardt, G. Becker, M. Patt, E. Hammerstein, K. Hartwig, and et al. Individualized quantification of brain beta-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls Eur J Nucl Med Mol Imaging 38 2011 1702 1714
11. V.L. Villemagne, K. Ong, R.S. Mulligan, G. Holl, S. Pejoska, G. Jones, and et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias J Nucl Med 52 2011 1210 1217
12. H. Barthel, H.J. Gertz, S. Dresel, O. Peters, P. Bartenstein, K. Buerger, and et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study Lancet Neurol 10 2011 424 435
13. C.C. Rowe, U. Ackerman, W. Browne, R. Mulligan, K.L. Pike, G. O'Keefe, and et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism Lancet Neurol 7 2008 129 135
14. G.A. Becker, M. Ichise, H. Barthel, J. Luthardt, M. Patt, A. Seese, and et al. PET quantification of 18F-florbetaben binding to beta-amyloid deposits in human brains J Nucl Med 54 2013 723 731
15. S.S. Mirra, A. Heyman, D. McKeel, S.M. Sumi, B.J. Crain, L.M. Brownlee, and et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease Neurology 41 1991 479 486
16. T. Yamamoto, and A. Hirano A comparative study of modified Bielschowsky, Bodian and thioflavin S stains on Alzheimer's neurofibrillary tangles Neuropathol Appl Neurobiol 12 1986 3 9
17. J.N. Rao, and A.J. Scott A simple method for the analysis of clustered binary data Biometrics 48 1992 577 585
18. J.L. Fleiss Statistical methods for rates and proportions 2nd ed. 1981 John Wiley & Sons Ltd Hoboken, NJ
19. H. Braak, and E. Braak Neuropathological staging of Alzheimer-related changes Acta Neuropathol 82 1991 239 259
20. P. Scheltens, D. Leys, F. Barkhof, D. Huglo, H.C. Weinstein, P. Vermersch, and et al. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates J Neurol Neurosurg Psychiatry 55 1992 967 972
21. T.G. Beach, S.E. Monsell, L.E. Phillips, and W. Kukull Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010 J Neuropathol Exp Neurol 71 2012 266 273
22. C.M. Clark, J.A. Schneider, B.J. Bedell, T.G. Beach, W.B. Bilker, M.A. Mintun, and et al. Use of florbetapir-PET for imaging beta-amyloid pathology JAMA 305 2011 275 283
23. C.M. Clark, M.J. Pontecorvo, T.G. Beach, B.J. Bedell, R.E. Coleman, P.M. Doraiswamy, and et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study Lancet Neurol 11 2012 669 678
24. B. Stankoff, L. Freeman, M.S. Aigrot, A. Chardain, F. Dollé, A. Williams, and et al. Imaging central nervous system myelin by positron emission tomography in multiple sclerosis using [methyl-(1)(1)C]-2-(4'-methylaminophenyl)- 6-hydroxybenzothiazole Ann Neurol 69 2011 673 680
25. D.R. Thal, W.S. Griffin, and H. Braak Parenchymal and vascular Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease J Cell Mol Med 12 2008 1848 1862
26. B.T. Hyman, C.H. Phelps, T.G. Beach, E.H. Bigio, N.J. Cairns, M.C. Carrillo, and et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease Alzheimers Dement 8 2012 1 13
27. M.N. Sabbagh, A. Fleisher, K. Chen, J. Rogers, C. Berk, E. Reiman, and et al. Positron emission tomography and neuropathologic estimates of fibrillar amyloid-beta in a patient with Down syndrome and Alzheimer disease Arch Neurol 68 2011 1461 1466
28. M.D. Ikonomovic, W.E. Klunk, E.E. Abrahamson, C.A. Mathis, J.C. Price, N.D. Tsopelas, and et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease Brain 131 Pt 6 2008 1630 1645
29. V.L. Villemagne, R.S. Mulligan, S. Pejoska, K. Ong, G. Jones, G. O'Keefe, and et al. Comparison of 11C-PiB and 18F-florbetaben for Abeta imaging in ageing and Alzheimer's disease Eur J Nucl Med Mol Imaging 39 2012 983 989
30. C.G. Schipke, O. Peters, I. Heuser, T. Grimmer, M.N. Sabbagh, O. Sabri, and et al. Impact of beta-amyloid-specific florbetaben PET imaging on confidence in early diagnosis of Alzheimer's disease Dement Geriatr Cogn Disord 33 2012 416 422
31. M.T. Fodero-Tavoletti, D. Brockschnieder, V.L. Villemagne, L. Martin, A.R. Connor, A. Thiele, and et al. In vitro characterization of [18F]-florbetaben, an Abeta imaging radiotracer Nucl Med Biol 39 2012 1042 1048